Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology Inc. (MAIA) is a clinical-stage biopharmaceutical company pioneering targeted cancer therapies through novel telomere science and immune-oncology research. This page provides investors and researchers with verified updates on MAIA's therapeutic advancements, corporate developments, and clinical progress.
Access timely announcements including clinical trial milestones, regulatory updates, financial reports, and strategic partnerships. Our curated news collection offers comprehensive insights into MAIA's diversified pipeline and R&D strategy while maintaining strict compliance with financial disclosure standards.
Key updates cover developments across MAIA's therapeutic programs, including its telomere-targeting THIO initiative, partnership announcements, and progress reports from dedicated research subsidiaries. Content is organized for quick scanning while maintaining scientific accuracy for both professional and non-specialist audiences.
Bookmark this page for streamlined access to MAIA's latest verified developments. For complete investment information, always consult official SEC filings alongside these news resources.
MAIA Biotechnology (NYSE American: MAIA) has reported promising updates on disease control data in the Part A safety lead-in of its ongoing THIO-101 phase 2 trial. The trial is evaluating THIO in sequential combination with cemiplimab for patients with advanced Non-Small Cell Lung Cancer (NSCLC) who have previously failed 2 or more prior lines of treatment.
Key findings include:
- 82% disease control rate: 9 out of 11 patients with post-baseline scans met the primary endpoint of disease control
- Disease control is defined as Complete Response, Partial Response, or Stable Disease per RECIST 1.1
- All patients had previously failed immune checkpoint inhibitor (CPI) and platinum-based chemotherapy treatments
- No new safety analysis was conducted at this time
The company's CEO, Vlad Vitoc, expressed encouragement with these preliminary results, noting that they align with pre-clinical data showing THIO's potential to enhance CPI effectiveness in resistant cases.